Karyopharm initiates pivotal phase 3 study of xpo1 inhibitor selinexor and ruxolitinib in jak inhibitor (jaki) naÏve myelofibrosis

Phase 3 study is supported by previously presented phase 1 study results, including a 78.6% svr35 and 58.3% tss50 in intent to treat patients at week 24 at the 60mg dose newton, mass. , june 28, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the initiation of a pivotal phase 3 clinical trial (xport-mf-034) (nct04562389) to assess the efficacy and safety of once-weekly selinexor 60mg in combination with ruxolitinib in jaki-naÏve patients with myelofibrosis.
KPTI Ratings Summary
KPTI Quant Ranking